1
Simon F Williams, David P Martin, Tillman Gerngross, Daniel M Horowitz: Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation. Metabolix, Arnall Golden & Gregory, June 12, 2001: US06245537 (127 worldwide citation)

Polyhydroxyalkanoate (PHA) that contains a pyrogen such as endotoxin due to a process of producing the PHA is treated to remove the pyrogen by a process that does not affect the inherent chemical and physical properties of the PHA to obtain a biocompatible PHA. PHA produced by fermentation with a Gr ...


2
Simon F Williams, David P Martin, Tillman Gerngross, Daniel M Horowitz: Medical device containing polyhydroxyalkanoate treated with oxidizing agent to remove endotoxin. Metabolix, Holland & Knight, September 23, 2003: US06623749 (46 worldwide citation)

Polyhydroxyalkanoate (PHA) that contains a pyrogen such as an endotoxin due to a process of producing the PHA is treated to remove the pyrogen by a process that does not affect the inherent chemical and physical properties of the PHA to obtain a biocompatible PHA. PHA produced by fermentation with a ...


3
Simon F Williams, David P Martin, Tillman Gerngross, Daniel M Horowitz: Method for making devices using polyhydroxyalkanoate having pyrogen removed. Metabolix, Pabst Patent Group, July 17, 2007: US07244442 (30 worldwide citation)

Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial syst ...


4
Juergen Nett, Tillman Gerngross: ARG1, ARG2, ARG3, HIS1, HIS2, HIS5, HIS6 genes and methods for stable genetic integration. GlycoFi, John David Reilly, Catherine D Fitch, William Krovatin, January 20, 2009: US07479389 (7 worldwide citation)

Novel genes encoding P. pastoris ARG1, ARG2, ARG3, HIS1, HIS2, HIS5 and HIS6 are disclosed. A method for inactivating alternately at least two biosynthetic pathways in a methylotrophic yeast is provided. A method for producing and selecting yeast strains characterized as being capable of genetic int ...


5
Simon F Williams, David P Martin, Tillman Gerngross, Daniel M Horowitz: Method of forming medical devices having pyrogen removed for in vivo application. Metabolix, Pabst Patent Group, July 31, 2012: US08231889 (5 worldwide citation)

Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial syst ...


6
Simon F Williams, David P Martin, Tillman Gerngross, Daniel M Horowitz: Medical device comprising polyhydroxyalkanoate having pyrogen removed. Metabolix, Pabst Patent Group, March 15, 2011: US07906135 (1 worldwide citation)

Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial syst ...


7
Robert Davidson, Tillman Gerngross, Stefan Wildt, Byung Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen Robin Hamilton: Production of galactosylated glycoproteins in lower eukaryotes. Glycofi, August 26, 2014: US08815544

The present invention provides a novel lower eukaryotic host cell producing human-like glycoproteins characterized as having a terminal β-galactose residue and essentially lacking fucose and sialic acid residues. The present invention also provides a method for catalyzing the transfer of a galactose ...


8
Simon F Williams, David P Martin, Tillman Gerngross, Daniel M Horowitz: Polyhydroxyalkanoates for in vivo applications. Arnall Golden & Gregory, July 26, 2001: US20010009769-A1

Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial syst ...


9
Simon F Williams, David P Martin, Tillman Gerngross, Daniel M Horowitz: Polyhydroxyalkanoates for in vivo applications. Metabolix, Patrea L Pabst, Holland & Knight, March 18, 2004: US20040053381-A1

Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial syst ...


10
Simon F Williams, David P Martin, Tillman Gerngross, Daniel M Horowitz: Polyhydroxyalkanoates for In Vivo Applications. Metabolix, Patrea L Pabst, Pabst Patent Group, December 6, 2007: US20070280899-A1

Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial syst ...